Low Libido: When to See a Doctor and What's Actually Causing It

What "Low Libido" Actually Means for Women

Low libido means your sexual desire is lower than you want it to be, and that gap is causing you distress. Doctors call the clinical form Hypoactive Sexual Desire Disorder, or HSDD, defined as persistently reduced or absent sexual thoughts, fantasies, or desire for sexual activity with personal distress attached to it. The distress part matters: a woman who is not bothered by a low sex drive does not have a disorder.

HSDD affects roughly 8 to 14% of U.S. Women depending on age and the measure used, but broader surveys of sexual dysfunction capture a much wider net. The PRESIDE study found that 43.1% of women reported at least one sexual problem, with low desire being the most common complaint, present in about 39% of respondents.

What separates a temporary dip from a problem worth addressing is three things: duration of at least three months, personal distress, and the absence of another condition that explains it fully on its own. You are the authority on whether the distress is real.

How Female Desire Works (and Why It Is Different)

Women's sexual desire is less often spontaneous and more often responsive than men's. Researcher Rosemary Basson published a circular model of female sexual response in 2000 showing that many women begin a sexual encounter from a neutral rather than aroused baseline, and that intimacy, context, and relationship cues shift them toward desire, not the other way around. Her model is now embedded in most clinical guidelines on female sexual dysfunction. Recognizing this means your experience of desire may look different from what popular culture depicts, and that is not pathological.

The Most Common Causes of Low Libido in Women

Hormonal Causes

Hormones are the most frequently identified physiological driver. Estrogen supports vaginal tissue, clitoral blood flow, and genital sensation. Testosterone, often thought of as a male hormone, drives sexual motivation in women too. Women produce testosterone in the ovaries and adrenal glands, with levels peaking in the mid-twenties and declining steadily after that.

Key hormonal triggers include:

• Menopause and perimenopause. Estradiol falls by roughly 85 to 90% across the menopause transition. Testosterone also declines. The result is often reduced desire, genitourinary syndrome of menopause (GSM), and dyspareunia, each of which feeds into the others.
• Postpartum and lactation. Prolactin rises sharply to support milk production and suppresses GnRH, dropping estrogen and testosterone. Breastfeeding women show significantly lower sexual desire and satisfaction compared to non-breastfeeding postpartum women. This is physiologically expected and usually resolves when lactation ends or is reduced.
• Hormonal contraception. Combined oral contraceptives raise sex hormone-binding globulin (SHBG), which binds free testosterone. A 2006 study in the Journal of Sexual Medicine found that SHBG remained elevated even after stopping the pill, suggesting the effect may persist months beyond discontinuation in some women.
• PCOS. Polycystic ovary syndrome is associated with both hormonal imbalance and psychological burden that can suppress desire. Androgen excess may sound like it would boost libido, but the chronic stress of living with PCOS, plus insulin resistance and body image concerns, often works the other way. Research in Fertility and Sterility found lower sexual satisfaction scores in women with PCOS compared to matched controls.
• Thyroid dysfunction. Both hypothyroidism and hyperthyroidism alter libido. Hypothyroidism slows metabolism, lowers mood, and reduces genital sensitivity. Thyroid function is a standard part of any low-libido workup.

Mental Health and Psychological Causes

Depression is among the strongest predictors of low libido in women. Anxiety, chronic stress, body image disturbance, history of sexual trauma, and relationship dissatisfaction all independently reduce sexual desire. A meta-analysis in JAMA Psychiatry confirmed that depression significantly reduces sexual desire across sexes, though women report the intersection more often.

The complication: the antidepressants most often prescribed for depression, SSRIs and SNRIs, also suppress libido. Sertraline, escitalopram, and venlafaxine are the most commonly implicated. This creates a clinical paradox where treating depression worsens sexual function. Bupropion is one alternative with a lower sexual side-effect profile and is sometimes used specifically as an adjunct to address SSRI-induced low libido, as supported by a randomized trial in Annals of Internal Medicine.

Relationship and Situational Causes

Sex does not happen in a vacuum. Relationship conflict, poor emotional intimacy, mismatched desire between partners, communication problems, and lack of privacy (common in new parenthood) all reduce desire reliably. A woman does not need a hormonal diagnosis to experience real, significant low libido driven entirely by context.

Research consistently shows that relationship satisfaction is one of the most powerful predictors of female sexual desire. A prospective study of 170 couples found that women's desire, more than men's, tracked closely with emotional closeness and relationship quality over time.

Medications That Suppress Desire

Many commonly prescribed medications list low libido as a side effect. The most clinically significant include:

• SSRIs and SNRIs (as above)
• Combined hormonal contraceptives (via SHBG elevation)
• Beta-blockers (propranolol, metoprolol)
• Anticonvulsants (valproate, carbamazepine)
• Opioids and long-term opioid therapy
• GnRH agonists like leuprolide (used in endometriosis and fibroids)
• Certain antipsychotics that raise prolactin

If you started a new medication within weeks of noticing a change in desire, bring that timeline to your provider.

Low Libido by Life Stage

Reproductive Years (Ages 18 to ~42)

In your reproductive years, low libido is most often tied to hormonal contraception, stress, depression, a new relationship dynamic, or subclinical thyroid disease. PCOS is underdiagnosed in this age group and is worth testing for if you also have irregular cycles, acne, or unwanted hair growth.

Cycle phase matters too. Desire naturally peaks around ovulation, driven by a mid-cycle testosterone surge and peak estradiol. If you notice your desire is essentially zero in the luteal phase, that pattern can point toward premenstrual dysphoric disorder (PMDD) or progesterone sensitivity rather than a global libido problem.

Trying to Conceive

Paradoxically, the pressure of timed intercourse often suppresses desire. Sex becomes task-oriented, spontaneity disappears, and stress hormones interfere with the hormonal signals of arousal. ASRM guidelines acknowledge the psychological burden of infertility treatment and recommend counseling as a standard part of care, not an afterthought.

Postpartum and Lactation

Expect low libido postpartum. Estrogen drops precipitously after delivery. Breastfeeding compounds this by keeping estrogen suppressed. Vaginal dryness and perineal healing create physical barriers. Sleep deprivation, identity shifts, and caregiver exhaustion add to the picture. Low libido in the first six to twelve months postpartum is essentially universal.

See your provider if low desire is accompanied by mood disturbance (possible postpartum depression), if it persists beyond twelve months post-weaning, or if vaginal dryness is causing pain that affects your daily life independent of sex.

Perimenopause (Average Age 47 to 51)

Perimenopause, the years before your final menstrual period, is the life stage most reliably associated with declining libido. Estrogen fluctuates wildly before dropping. Testosterone falls. Sleep disruption from vasomotor symptoms (hot flashes, night sweats) is chronic and underrecognized as a libido suppressant. The SWAN (Study of Women's Health Across the Nation) cohort found that sexual desire and frequency both declined significantly across the menopausal transition, independent of age alone.

GSM, formerly called vulvovaginal atrophy, develops as estrogen falls and makes sex physically uncomfortable or painful. Pain during sex feeds avoidance, which further reduces desire. Treating GSM often improves libido directly.

Postmenopause

After the final menstrual period, lower estrogen and testosterone become the baseline. Low libido is common but not inevitable. Systemic menopausal hormone therapy (MHT), vaginal estrogen, and off-label testosterone therapy each address different parts of the picture. The Menopause Society (formerly NAMS) recommends that all postmenopausal women with bothersome sexual symptoms be offered treatment and that the conversation not be dismissed as a normal part of aging.

When to Actually Worry: Red Flags and the "See a Doctor Now" List

Most low libido does not represent a medical emergency. But certain combinations of symptoms mean you should book an appointment within weeks, not months.

See a clinician within four weeks if:

• Low desire has lasted more than three months and is causing you distress
• You have new pelvic pain or pain with intercourse
• Vaginal dryness is interfering with daily comfort, not just sex
• You have new or worsening depression, anxiety, or mood swings alongside the low libido
• Your menstrual cycle has changed significantly (skipped periods, very heavy bleeding, new spotting)
• You are taking a medication known to suppress desire and have never had this addressed
• You are postmenopausal and have never discussed sexual health with your provider

See a clinician within one to two weeks if:

• Low libido is paired with fatigue, cold intolerance, weight gain, or constipation (thyroid screening needed)
• You have signs of PCOS you have never had evaluated
• Low desire is accompanied by galactorrhea (spontaneous breast milk when not postpartum or breastfeeding), which may indicate elevated prolactin

The bottom line: if it is bothering you, that alone is enough reason to ask for help.

How Low Libido Is Diagnosed

There is no blood test that confirms HSDD. Diagnosis is clinical, meaning it is based on your history. A thorough evaluation should include:

The Conversation

Your clinician should ask about onset, duration, whether desire was ever different, relationship context, stress, mood, sleep, and any medications. The Female Sexual Function Index (FSFI) and the HSDD screener (the Decreased Sexual Desire Screener, or DSDS) are validated tools used to structure that conversation. You can ask your provider to use one of these.

Laboratory Testing

Standard labs for low libido in women typically include:

• TSH and free T4 (thyroid)
• Total and free testosterone
• SHBG (especially if on hormonal contraceptives)
• Prolactin
• FSH and estradiol (to assess menopausal status)
• Fasting glucose and insulin if PCOS is suspected
• Complete metabolic panel

There is no universally agreed "low" testosterone threshold for women, which is one reason the diagnosis relies on clinical picture rather than a single number. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 process-of-care recommendations note this explicitly and advise against treating to a lab value alone.

Ruling Out Contributing Conditions

Screening for depression (PHQ-9), anxiety (GAD-7), and a thorough pelvic exam to assess for GSM, vaginismus, or pelvic floor dysfunction round out the evaluation. If endometriosis or fibroids are suspected from your history, imaging may be added.

What Treatment for Low Libido Looks Like

Treatment is not one-size-fits-all and depends heavily on the cause and your life stage.

FDA-Approved Options for HSDD

Two medications carry FDA approval specifically for HSDD in premenopausal women:

• Flibanserin (Addyi), 100 mg taken nightly. A non-hormonal agent that modulates serotonin and dopamine. A pooled analysis of three Phase 3 trials found statistically significant improvement in satisfying sexual events, desire scores, and distress compared to placebo, though the absolute effect size was modest. Alcohol must be avoided due to risk of severe hypotension. Not approved for postmenopausal women.
• Bremelanotide (Vyleesi), 1.75 mg subcutaneous injection taken as needed before sex. A melanocortin receptor agonist. FDA prescribing information notes it is contraindicated in women with cardiovascular disease and may cause transient blood pressure increases. Also approved only for premenopausal women.

Neither drug is approved during pregnancy. Both carry specific safety warnings that require discussion with a clinician.

Testosterone Therapy (Off-Label)

Testosterone is not FDA-approved for women in the United States, but it is widely used off-label, particularly in postmenopausal women. The ISSWSH 2019 global consensus supports testosterone therapy for postmenopausal women with HSDD when other causes have been excluded, using physiologic doses targeting a premenopausal normal range. A systematic review in The Lancet Diabetes and Endocrinology of 36 randomized trials found testosterone significantly improved sexual function in women, including desire, arousal, and orgasm, with no increase in serious adverse events at physiologic doses.

Menopausal Hormone Therapy and Vaginal Estrogen

For perimenopausal and postmenopausal women, systemic MHT addresses the estrogen deficiency that underlies much of the libido decline and GSM. Vaginal estrogen (cream, tablet, or ring) targets local tissue without significant systemic absorption and is considered safe even for women with a history of hormone-sensitive cancers by some guidelines, though that conversation requires individualized review.

Non-Pharmacological Approaches

Psychotherapy, specifically cognitive behavioral therapy (CBT) and sex therapy, has strong evidence for female sexual dysfunction. A Cochrane review of psychosocial interventions for female sexual dysfunction found CBT and mindfulness-based approaches improved sexual desire and satisfaction. These approaches are particularly effective when relationship factors or anxiety are prominent drivers.

Mindfulness-based sex therapy developed by Lori Brotto is one of the most studied non-pharmacological approaches for women and has shown meaningful benefit in multiple randomized trials.

Pelvic floor physical therapy is indicated when low desire is partly driven by anticipatory pain from pelvic floor dysfunction or GSM.

The Evidence Gap: What We Do Not Know Yet

Women have been chronically underrepresented in sexual health research. Most major drug trials used men as default subjects until the 1990s, and even now, female sexual dysfunction receives a fraction of the research funding directed at male erectile dysfunction. Several practical consequences follow from this:

• Testosterone dosing guidelines for women are extrapolated from postmenopausal surgical-menopause cohorts, not from large reproductive-age trials.
• Nearly all HSDD trial data comes from heterosexual, predominantly white women. Whether findings apply equally across sexual orientations, race, and ethnicity is genuinely unknown.
• Flibanserin's modest effect size in trials partly reflects how difficult it is to study subjective desire in controlled conditions where the tool used to measure "satisfying sexual events" may not capture how women actually experience desire.
• Long-term safety data for testosterone in women beyond two years remains thin.

When your clinician recommends a treatment, asking "was this studied in women like me" is a reasonable and intelligent question.

Who This Is Right For and Who Should Wait

Good Candidates for Evaluation and Treatment

You are a good candidate to pursue evaluation if you are experiencing low desire that has lasted more than three months, you are distressed by it, and you want it addressed. That applies whether you are 25 and postpartum, 38 and on oral contraceptives, or 55 and postmenopausal.

Life stages where active treatment is especially supported by evidence:

• Postmenopausal women: MHT, vaginal estrogen, off-label testosterone
• Perimenopausal women: MHT, testosterone, GSM treatment
• Premenopausal women with HSDD: Flibanserin, bremelanotide, CBT, contraceptive review

Situations That Need Careful Discussion First

• Women actively trying to conceive: Neither flibanserin nor bremelanotide should be used while attempting pregnancy. Sex therapy and addressing relationship dynamics are first-line.
• Women who are pregnant: No pharmacological HSDD treatment is approved or recommended in pregnancy. Libido changes during pregnancy are common and usually do not require intervention beyond reassurance and pelvic floor support for dyspareunia.
• Women breastfeeding: Vaginal moisturizers and lubricants are safe. Low-dose vaginal estrogen has limited systemic absorption and is generally considered acceptable, but discuss with your provider. Systemic hormones require individualized risk-benefit discussion.
• Women with hormone-sensitive cancers: Careful individualized review with an oncologist and gynecologist before any hormonal therapy.

Pregnancy and Lactation: The Specifics

Because low libido treatment often involves hormonal or pharmacological agents, this section applies directly to any woman of reproductive age seeking treatment.

Flibanserin (Addyi): No adequate human pregnancy data exists. Animal studies showed fetal harm at high doses. FDA labeling recommends discontinuing flibanserin as soon as pregnancy is confirmed. Lactation data is absent; the FDA recommends against use during breastfeeding.

Bremelanotide (Vyleesi): FDA prescribing information states that animal reproduction studies showed fetal harm. Bremelanotide is not recommended during pregnancy. Lactation transfer is unknown; avoid during breastfeeding.

Testosterone (off-label): Testosterone is teratogenic. FDA categorizes androgens as Pregnancy Category X, meaning fetal risk outweighs any possible benefit. Women using testosterone therapy must use reliable contraception if there is any chance of pregnancy. Testosterone is detectable in breast milk and is generally avoided during lactation.

Vaginal estrogen: Systemic absorption is very low with approved low-dose formulations. No significant fetal risk has been documented, but use in pregnancy is generally not indicated because the indication (GSM) does not apply during pregnancy. Minimal lactation transfer is expected but routine use is not recommended.

Any woman of reproductive potential starting hormonal therapy for low libido should have a clear contraception plan confirmed at the time of prescription.